Used in 8.4% of symptomatic patients in Michigan series, specifically those with hepatotoxicity or neurotoxicity
Dosing for active seizures
25 mg/kg IV infused over 15–30 minutes
Maximum single dose approximately 5 g in adults
Repeat dose if seizures persist after initial dose
Class IIa recommendation based on expert consensus and mechanistic evidence
Prophylactic dosing for confirmed ingestion with neurologic symptoms
25 mg/kg IV empirically even before seizure onset
Lower threshold for pediatric patients and high-dose ingestion
Limitations
Does not address hepatotoxicity directly
May not fully abort severe refractory seizures without benzodiazepines
Seizure management
Benzodiazepines as first-line adjunct
Lorazepam IV
0.1 mg/kg IV (typical adult dose 2–4 mg)
Repeat every 5 minutes to max 0.2 mg/kg
Preferred in hospital setting for seizure termination
Diazepam IV
0.2 mg/kg IV (typical adult dose 5–10 mg)
Rectal or IM route if IV access unavailable
Midazolam IM
10 mg IM for adults if no IV access
Pediatric dose 0.2 mg/kg IM
Refractory status epilepticus protocol
Levetiracetam IV
60 mg/kg IV over 15 minutes (max 4500 mg)
Avoid phenytoin as first add-on (mechanism does not address GABA deficit)
Phenobarbital IV
20 mg/kg IV at 50–100 mg/min
Respiratory depression monitoring required
Propofol infusion for refractory status
1–2 mg/kg IV bolus then 20–200 mcg/kg/min infusion
Requires intubation and mechanical ventilation
EEG monitoring for burst suppression endpoint
Hepatotoxicity management
N-acetylcysteine (NAC)
Empiric consideration for hepatoprotection
No controlled data specific to gyromitrin toxicity
Extrapolated from acetaminophen hepatotoxicity and other oxidant hepatic injuries
Low risk profile supports empiric use when hepatotoxicity present
IV protocol (if using)
Loading dose 150 mg/kg IV over 60 minutes
Maintenance 50 mg/kg IV over 4 hours then 100 mg/kg over 16 hours
Continue until hepatic function improving or transplant undertaken
Coagulopathy management
Vitamin K
10 mg IV or SC daily for 3 days
Ensures adequate substrate for coagulation factor synthesis
Fresh frozen plasma
Reserve for active bleeding or INR > 2 with planned invasive procedure
Do not give prophylactically — obscures INR trend used for prognosis
Cryoprecipitate
For fibrinogen < 1.5 g/L with active bleeding
Dose: 1 unit per 10 kg body weight
Hepatic encephalopathy management
Lactulose
30–45 mL PO or NG every 1–2 hours until bowel movement then every 8–12 hours
Target 2–4 soft stools daily
Rifaximin
550 mg PO twice daily as adjunct for grade II or higher encephalopathy
Avoid sedatives, opioids, and hepatotoxic medications
Liver transplant evaluation
Early referral if meeting King's College Criteria or MELD > 25
Ideally within 24 hours of acute liver failure diagnosis
Contraindications: active infection, multi-organ failure without hepatic basis
Methemoglobinemia treatment
Methylene blue
Indications
Methemoglobin level > 20% or symptomatic at lower levels
Symptoms: cyanosis, dyspnea, altered mental status despite adequate SpO2
Dosing
1–2 mg/kg IV over 5 minutes
Repeat in 1 hour if inadequate response
Maximum cumulative dose 7 mg/kg
Contraindications
G6PD deficiency — methylene blue may worsen hemolysis
Serotonin syndrome risk if serotonergic medications present
Supportive care
Fluid and electrolyte resuscitation
IV crystalloid for volume depletion from GI losses
Isotonic saline or balanced crystalloid
Titrate to hemodynamic response and urine output >= 0.5 mL/kg/h
Electrolyte replacement
Potassium replacement for hypokalemia (maintain K+ 3.5–5 mmol/l)
Magnesium 2 g IV if hypomagnesemia or refractory hypokalemia
Glucose management
Dextrose 10% infusion if hypoglycemia from hepatic failure
Target glucose 4–10 mmol/l
Antiemetics
Ondansetron 4–8 mg IV every 6–8 hours for nausea and vomiting
QTc monitoring if prolongation risk present
Metoclopramide 10 mg IV as alternative
Hemolysis management
Packed red blood cells if hemoglobin < 70 g/L or symptomatic anemia
Hemolysis occurs in approximately 2.5% of cases
Adequate IV hydration to prevent hemoglobin precipitation in renal tubules
Renal protection
Avoid nephrotoxic medications: NSAIDs, aminoglycosides, IV contrast
Hepatorenal syndrome management with nephrology input if creatinine rises
Continuous renal replacement therapy if severe acute kidney injury
Special Populations
Pregnancy
Pregnancy-specific considerations
Maternal risk
Hepatic failure in pregnancy carries high maternal and fetal mortality
Gyromitrin hepatotoxicity indistinguishable from other acute hepatic failures
Differentiate from acute fatty liver of pregnancy and HELLP syndrome
Fetal risk
Maternal shock causes fetal hypoperfusion and distress
MMH as hydrazine derivative may have teratogenic potential — limited human data
Avoid unnecessary medications with uncertain fetal safety profiles
Treatment modifications
Pyridoxine IV: safe in pregnancy — vitamin B6 is used for hyperemesis gravidarum
Benzodiazepines: use at lowest effective dose; neonatal effects if near term
NAC: generally considered safe in pregnancy for hepatic indications
Methylene blue: avoid if possible — association with intestinal atresia (very limited data); risk-benefit discussion needed for severe symptomatic methemoglobinemia
Monitoring
Continuous fetal monitoring when gestational age >= 24 weeks
Obstetric consultation immediately for any pregnant patient
Maternal SpO2 >= 95% to maintain fetal oxygenation
Imaging
Ultrasound preferred for abdominal assessment
CT with abdominal shielding if urgently indicated
Geriatric
Older adult-specific considerations
Reduced hepatic reserve
Pre-existing reduction in CYP450 enzyme activity
Lower threshold for hepatic decompensation
More susceptible to drug-induced hepatic injury with co-medications
Volume status vulnerabilities
Lower total body water and reduced renal reserve
More rapid dehydration from vomiting and diarrhea
Higher risk of acute kidney injury from hypoperfusion
Medication adjustments
Reduce benzodiazepine doses by 25–50% to avoid prolonged sedation
QTc prolongation risk higher in older adults, especially with electrolyte disturbance
Renal dosing adjustments for all renally cleared medications
Baseline cognitive assessment
Delirium may mimic or mask encephalopathy
Collateral history from family or caregiver essential
Pre-existing cognitive impairment may confound neurologic assessment
Functional and social considerations
Foraging more common as recreational activity in older adults
Admission threshold lower given reduced physiologic reserve
Falls risk during ataxia or seizures — head injury screen
Pediatrics
Pediatric-specific considerations
Higher susceptibility per body mass
Smaller body mass means proportionally higher toxin exposure per kg
Lower glycogen reserves increase hypoglycemia risk in hepatic failure
More rapid progression to encephalopathy
Pyridoxine dosing
25 mg/kg IV same weight-based dose as adults
No strict upper limit in acute seizure setting
May require repeated doses given rapid distribution volume
Benzodiazepine dosing
Lorazepam 0.1 mg/kg IV (max 4 mg per dose)
Diazepam 0.2–0.5 mg/kg IV (max 10 mg per dose)
Midazolam 0.1 mg/kg IV (max 5 mg per dose)
Dehydration assessment
Weight-based fluid replacement for documented losses
Normal saline 20 mL/kg IV bolus for hemodynamic compromise
Maintenance fluids D5 0.9% NaCl or D5 LR with electrolyte monitoring
Methylene blue pediatric dosing
1–2 mg/kg IV same as adults, weight-based
G6PD testing when feasible before administration
Liver transplant listing
PELD (Pediatric End-Stage Liver Disease) score used instead of MELD
Pediatric hepatology and transplant consultation early in fulminant course
Foraging exposure context
Child protection consideration if parent fed child with known toxic mushroom
Safety planning and mandatory reporting obligations per jurisdiction
Background
Epidemiology
Geographic and seasonal distribution
Endemic regions
Northern Europe: Finland, Poland, Germany, Baltic states — highest incidence
North America: Great Lakes region (Michigan dominant), Pacific Northwest
Spring season foraging March–May coincides with false morel fruiting
Incidence data
Gyromitra poisoning accounts for approximately 11–17% of serious mushroom poisonings in Europe
Michigan 19-year longitudinal study: 118 Gyromitra ingestion cases reported to Poison Control
No deaths among 118 cases in Michigan series despite substantial hepatotoxicity rate
Misidentification frequency
False morel (Gyromitra esculenta) mistaken for true morel (Morchella) — most common cause
Morchella has honeycomb-pitted cap vs Gyromitra brain-like irregularly lobed cap
Mortality data
Published case series mortality approximately 29% reflecting publication bias toward severe cases
Poison center series reporting lower mortality suggest milder cases underdiagnosed
Seizures present in 82% of fatal cases as late finding
Pathophysiology
Toxin metabolism cascade
Gyromitrin hydrolysis in vivo
Gyromitrin hydrolyzed to N-methyl-N-formylhydrazine (MFH) in acidic gastric environment
MFH further metabolized to monomethylhydrazine (MMH)
MMH is the primary toxic metabolite responsible for clinical effects
Avoid alcohol completely for at least 4 weeks after recovery
Avoid acetaminophen (Tylenol) and ibuprofen until your doctor says your liver is normal
Eat light foods until nausea fully resolves
Small frequent meals as tolerated
No raw or processed mushrooms from the wild
Required follow-up blood tests
Return for liver blood tests (AST, ALT, bilirubin, INR) in 48–72 hours
These tests check if your liver is recovering properly
Even if you feel completely well, liver damage may continue
Repeat liver tests at 1 week and then until fully normal
Return to the emergency department immediately for any of these warning signs
Yellow color in your eyes or skin (jaundice)
Sign that liver is struggling
Very dark brown or tea-colored urine
Severe abdominal pain especially in the upper right side
Confusion, trouble thinking clearly, excessive sleepiness, or difficulty waking
Seizure or convulsion (call 911 immediately)
Vomiting that will not stop or inability to keep down fluids
Unusual bruising or bleeding that will not stop
Pale or clay-colored stools
Fever above 38.5 degrees Celsius
Important prevention information
Never eat wild mushrooms unless identified by a certified mycologist
The false morel (Gyromitra) looks similar to the edible morel — experts make mistakes too
When in doubt, throw it out
Boiling or cooking does not make false morels completely safe
The steam from boiling is also toxic — ventilate the kitchen or cook outdoors
Report your case to Poison Control (1-800-222-1222) to help protect others
They can track outbreaks and warn other foragers
References
Guidelines and key sources
Landmark studies and case series
Simon MW et al. Clinical Toxicology 2025 — narrative review of Morchella and Gyromitra ingestions
Largest recent systematic review of false morel poisoning clinical features
Characterizes GI, neurologic, and hepatic syndrome frequencies
Vohra V et al. Toxicon 2024 — 19-year longitudinal assessment of gyromitrin poisoning in Michigan
118 cases; documented GI (74.7%), neurologic (26.5%), hepatic (16.9%) involvement
Zero deaths; pyridoxine used in 8.4% of symptomatic patients
Michelot D, Toth B. Journal of Applied Toxicology 1991 — foundational review of Gyromitra esculenta poisoning
Defines toxin chemistry and mechanism of action
White J et al. Toxicon 2019 — proposed new clinical classification of mushroom poisoning
Organizes all mushroom toxidromes including gyromitrin syndrome
Toxicology references
Wennig R et al. Deutsches Arzteblatt International 2020 — mushroom poisoning comprehensive review
Emergency management recommendations including antidote protocols
Köppel C. Toxicon 1993 — clinical symptomatology and management of mushroom poisoning
Classic reference for treatment algorithms
Leathem AM, Dorran TJ. CJEM 2007 — Gyromitra esculenta poisoning west of the Rockies
North American case series highlighting regional presentation
Diagnostic and molecular identification
Xie X et al. Frontiers in Microbiology 2021 — LAMP-based molecular identification of Gyromitra
Rapid identification method using loop-mediated isothermal amplification
Flament E et al. Pharmaceuticals 2020 — analytical toxicology of mushroom poisoning
Reviews MMH detection methods and biological matrix analysis
Coding standards
ICD-10 T62.0 — toxic effects of ingested mushrooms
ICD-10 T62.0XXA — initial encounter
ICD-10 K72.00 — acute and subacute hepatic failure without coma
ICD-10 K72.01 — acute and subacute hepatic failure with coma
SNOMED CT 80690008 — poisoning by toxic food substance
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.